Telix Pharmaceuticals
The CMC Program Lead is responsible for leading the CMC Sub-Team and serving as the single point of contact for all CMC topics on the program matrix for early-stage antibody-conjugate radiopharmaceutical drug candidates. The CMC Lead will develop, execute, and maintain the integrated CMC strategy and plan grounded in Quality by Design (QbD) principles, aligned to Stage-Gate requirements, spanning Drug Substance, Drug Product, Analytical Development, and Supply Chain from preclinical development through end of phase 1 (first-in-human).
Headquarters
North Melbourne, Victoria, Australia
Company Size
201-500 employees
Founded
2015
Telix Pharmaceuticals is a global, commercial‑stage biopharmaceutical company developing diagnostic and therapeutic “theranostic” products that use targeted radiation to detect and treat cancer. It advances radiopharmaceuticals through clinical development, regulatory approval, manufacturing and commercialisation to bring imaging agents and targeted therapies to patients. Telix works with the nuclear medicine community and international partners to scale access and improve outcomes. Its stated mission is to help patients with cancer live longer with better quality lives.
TLX DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Dec 14, 2025
Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX
Nov 13, 2025
Pharma groups rush to calm investor fears over Trump’s tariff hit
Sep 26, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Telix Pharmaceuticals.
4% above the average for this role
The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31, 2025
CMC dossier leader
sanofi us
Executive Director, Regulatory Affairs CMC
State of Washington
Senior Manager, Regulatory Affairs CMC
Spyre Therapeutics
Director, CMC Product Development – Biologics
Beeline
Principal Scientist, Radiopharmaceutical Development/CMC
Bristol Myers Squibb
Senior Director, CMC Lead Product Development
Cytokinetics